
STATUTORY INSTRUMENTS

2019 No. 775

**The Human Medicines (Amendment
etc.) (EU Exit) Regulations 2019**

PART 5

Amendment of Part 5 (marketing authorisations)

Amendment of regulation 71 (withdrawal of medicinal product from the market)

80.—(1) Regulation 71 ^{M1} is amended as follows.

(2) In paragraph (1)—

(a) for sub-paragraph (a) substitute—

“(a) under regulation 68 the licensing authority revokes or suspends a UK marketing authorisation or parallel import licence; or”;

[^{F1}(b) for sub-paragraph (b) substitute—

“(b) under—

(i) regulation 69 the licensing authority suspends the use, sale, supply or offer for sale or supply within Great Britain of a product to which a UKMA(GB) relates; or

(ii) regulation 69 or Article 20(4) of Regulation (EC) No 726/2004 the licensing authority suspends the use, sale, supply or offer for sale or supply within Northern Ireland of a product to which a UKMA(NI) or UKMA(UK) relates.”.]

Textual Amendments

F1 Reg. 80(2)(b) substituted (31.12.2020 immediately before IP completion day) by [The Human Medicines \(Amendment etc.\) \(EU Exit\) Regulations 2020 \(S.I. 2020/1488\)](#), reg. 1, [Sch. 2 para. 58](#)

Commencement Information

I1 Reg. 80 in force at 31.12.2020 on IP completion day (in accordance with [2020 c. 1](#), [Sch. 5 para. 1\(1\)](#)), see [reg. 1](#)

Marginal Citations

M1 Regulation 71 was amended by [S.I. 2014/1878](#).

Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2019, Section 80.